Table 3.
Results - efficacy estimates.
| Total (N = 162) | IOT (N = 40) | TT (N = 122) | |
|---|---|---|---|
| 90 day mortality | 15 (9.3%) | 6 (15.0%) | 9 (7.4%) |
| TTF (months), median (95%CI) | 4.2 (3.4, 6.4) | 3.7 (2.3, 6.4) | 4.5 (3.6, 10.4) |
| OS (months), median (95%CI) | 26.6 (19.3, -) | 19.6 (5.2, -) | 33.3 (19.3, -) |
| Best Response | |||
| Complete Response | 15 (9.3%) | 2 (5.0%) | 13 (10.7%) |
| Partial Response | 27 (16.7%) | 7 (17.5%) | 20 (16.4%) |
| Stable Disease | 66 (40.7%) | 17 (42.5%) | 49 (40.2%) |
| Progressive Disease | 43 (26.5%) | 12 (30.0%) | 31 (25.4%) |
| Not Assessed | 11 (6.8%) | 2 (5.0%) | 9 (7.4%) |
| Stable disease (med,months) | 3.8 (0.4–29.1) | 3.5 (0.6–23.9) | 3.9 (0.4–29.1) |
| 0–3 months | 70 (43.2%) | 18 (45.0%) | 52 (42.6%) |
| 3–6 months | 32 (19.8%) | 8 (20.0%) | 24 (19.7%) |
| >6 months | 60 (37.0%) | 14 (35.0%) | 46 (37.7%) |
IOT: pts treated on immunotherapy clinical trials; TT: Pts treated on targeted therapy clinical trials; TTF:Time to treatment failure; OS Overall survival